



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/50	A1	(11) International Publication Number: WO 97/47289 (43) International Publication Date: 18 December 1997 (18.12.97)
(21) International Application Number: PCT/US97/09835 (22) International Filing Date: 9 June 1997 (09.06.97) (30) Priority Data: 08/662,870 12 June 1996 (12.06.96) US (71) Applicant: E-L MANAGEMENT CORPORATION [US/US]; 767 Fifth Avenue, New York, NY 10153 (US). (72) Inventors: KNIGHT, Althea; 308 Herrick Avenue, Teaneck, NJ 07666 (US). ZECCHINO, Julius; 30 Auryansen Court, Closter, NJ 07624 (US). SCHNITTGER, Steven; 10 Willettts Place, Huntington Station, NY 11746 (US). (74) Agents: FLINTOFT, Gerald, J. et al.; Pennic & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: STABILIZED HINOKITIOL AND COMPOSITIONS CONTAINING SAME (57) Abstract The present invention relates to cosmetic or pharmaceutical compositions containing a preservative-effective amount of hinokitiol-containing microcapsules, the microcapsules comprising a matrix containing collagen and a glycosaminoglycan.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

STABILIZED HINOKITIOL AND COMPOSITIONS CONTAINING SAME

Field of the Invention

The present invention relates to preservatives useful in pharmaceutical and cosmetic compositions. In particular, the invention relates to a stabilized, anti-irritant preservative, hinokitiol.

Background of the Invention

Contamination of pharmaceutical and cosmetic compositions by bacteria and/or fungi can present a serious problem to the formulator. To combat this problem, and in order to prolong shelf life of the product, such compositions frequently contain preservatives which have antimicrobial activity. Given the diverse chemical nature of the available preservatives, however, and the equally diverse nature of the compositions in which they are intended to be used, the ability to successfully use a given preservative in a particular formulation cannot be assumed.

One such preservative is the substance known as hinokitiol. [2-hydroxy-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one; isopropyltropolone]. Hinokitiol is a wood extract obtainable from pine, cedar, etc. Methods for its production are described, for example, in JP 0586396 and JP 05105898. This material is known to have potent antimicrobial effects, and, as such, has been previously used for a variety of purposes. For example, hinokitiol has been used in food preservation and prevention of discoloration (JP 78035145; JP 6277019; JP 6153788; JP 6090661; JP 5344861; JP 59085279); in combination with zinc, or with ethyl alcohol and propylene glycol for antisepsis and/or the treatment of infection (WO 9317559; JP 3133334); in detergent compositions (WO 9205240); and as a wood preservative (JP 1038203). Hinokitiol has also

SUBSTITUTE SHEET (RULE 26)

been used in various types of cosmetic and pharmaceutical compositions. For example, DE 4202964 discloses a water-phase hair and body treatment comprising hinokitiol and heliotropin or a cosmetic alcohol, wherein the heliotropin and alcohol is
5 said to synergistically enhance the antimicrobial activity of hinokitiol. Similarly, JP 2243607 describes the use in cosmetic compositions of a preservative containing hinokitiol in combination with phenoxyethanol and phthalate ester. In addition, as shown herein, hinokitiol also possesses a
10 heretofore unappreciated anti-irritancy effect.

Although hinokitiol has been shown to be an effective preservative under a wide variety of conditions, it is not itself completely stable under all conditions in which its use might be desired. For example, its use in compositions in
15 polyethylene plastic containers can result in a discolored and/or unpleasant-smelling product. It also may not be stable after direct contact with light or air. These are limitations which under ordinary circumstances would not be acceptable, and which would recommend against its use in a cosmetic
20 composition, where appearance and fragrance can be critical. Therefore, in order to fully exploit its useful properties as a preservative, there remains a need for a means by which hinokitiol can itself be stabilized in the desired composition, and yet retain its useful biological properties, such as
25 antimicrobial and anti-irritant activity. The present invention provides the means by which hinokitiol can be effectively used in cosmetic compositions.

SUMMARY OF THE INVENTION

30 The present invention provides cosmetic and pharmaceutical compositions containing hinokitiol-containing microcapsules, the microcapsules comprising a matrix containing collagen and a glycosaminoglycan. The microcapsule provides adequate

stability to the hinokitiol, preventing it from discoloration and unpleasant odor in the composition containing same, while nonetheless permitting the hinokitiol to exert its preservative and anti-irritant effect on the composition containing it. The invention also provides a method for preserving a cosmetic or pharmaceutical composition, comprising adding to the composition a preservative-effective amount of the hinokitiol containing microcapsules, as well as a method for reducing irritation on the skin by application of a cosmetic composition containing an effective amount of hinokitiol-containing microspheres.

DETAILED DESCRIPTION OF THE INVENTION

The microcapsules used in the present invention are prepared according to the methodology disclosed in US Patent No. 5,395,620, the contents of which are incorporated herein by reference. Briefly, the microcapsules are prepared by combining a solution containing atelocollagen and a solution containing a polyholoside, preferably a glycosaminoglycan, in the presence of the hinokitiol and a crosslinking agent.

Atelocollagen is a type of collagen from which the telopeptides which crosslink typical collagen have been removed. The glycosaminoglycans are well known in the art, and for the present purposes may be selected, for example, from chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, heparin and derivatives thereof; preferably the cosmetically or pharmaceutically acceptable salts, such as calcium or sodium salts, are employed. The amount of glycosaminoglycan present in the microcapsules will typically be about 15-50% by weight of the atelocollagen used in the formulation. In absolute terms, the amount of atelocollagen in the starting solution is approximately 0.5-2% by weight, and the glycosaminoglycan solution contains about 0.5-4%, preferably 0.5-2% by weight of glycosaminoglycans. In

a particularly preferred embodiment, both the atelocollagen and the glycosaminoglycans are of marine origin. Cross-linking reagents useful in preparing the microcapsules include, but are not limited to, an acid dichloride, an acid anhydride, or a
5 dibasic or polybasic carboxylic acid. With respect to the hinokitiol, this material is present in an amount of between 0.01-10% by weight, preferably 0.5-4% by weight, of the starting solution.

The microcapsules containing hinokitiol provide an
10 unexpectedly high level of preservative efficacy, while itself remaining stable in the compositions in which it is included. The retention of antimicrobial activity, at the levels seen herein, is particularly surprising in view of the fact that the hinokitiol itself is not expected to be in direct contact with
15 the medium is intended to preserve. The microcapsules in which the hinokitiol is contained are essentially impermeable, i.e., there is apparently substantially no leakage of the hinokitiol into the medium in which the microcapsules are contained, as evidenced by the absence of unpleasant odor or color in the
20 products containing them. Since the hinokitiol is used in quantities essentially the same as used in its unencapsulated form, the substantially complete retention of antimicrobial activity by the "protected" hinokitiol is quite unexpected.

The encapsulated hinokitiol can be used in a wide variety
25 of cosmetic and/or pharmaceutical compositions, as well as a preservative in food compositions. In particular, the hinokitiol can be used in virtually any form in which such compositions may be formulated, e.g., solutions, colloidal dispersions, emulsions, suspensions, creams, lotions, gels,
30 foams, mousses and the like. Methods and components for preparing such compositions are well known in the art, and can be found for example, in CTFA International Cosmetics Ingredients Dictionary, The Cosmetic, Toiletry, and Fragrance

Association, Washington, DC, 1991. The amount of the hinokitiol-containing microspheres will vary depending on the nature of the composition and the amount of hinokitiol contained in the microspheres, but a preservative-effective amount of hinokitiol per se will generally be in the range of from about 0.1-1% by weight of the composition as a whole, given the amount of hinokitiol in the microspheres is as stated above. It is well within the skill of the art to determine the desired microsphere concentration in the formulation, given these parameters.

The compositions of the present invention will also comprise a pharmaceutically or cosmetically acceptable carrier, in an amount appropriate to accomodate the other components of the formulation. The term "pharmaceutically or cosmetically acceptable carrier" refers to a vehicle, for either pharmaceutical or cosmetic use, which vehicle delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms. As used herein, "pharmaceutical" or "cosmetic" will be understood to encompass both human and animal pharmaceuticals or cosmetics. The carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions, suspensions, creams, lotions, gels, foams, mousses and the like.

In a preferred embodiment, the carrier is a suspension, dispersion or emulsion. The emulsion may be an oil-in-water emulsion, or a water-in-oil emulsion. These emulsions contain one or more oil components, an aqueous component, and a specific emulsifier component chosen depending on the nature of the desired emulsion.

The oil component may be any pharmaceutically or cosmetically acceptable material which is substantially insoluble in water. These materials can be found for example in

SUBSTITUTE SHEET (RULE 26)

the CTFA International Dictionary of Cosmetic Ingredients as well as the U.S. Pharmacopoeia or equivalent sources. Suitable oil components include, but are not limited to, natural oils, such as coconut oil; hydrocarbons, such as mineral oil and hydrogenated polyisobutene; fatty alcohols, such as octyldodecanol; esters, such as C12-15 alkyl benzoate; diesters, such as propylene glycol dipelargonate; triesters, such as glyceryl trioctanoate; sterol derivatives, such as lanolin; animal waxes, such as beeswax; plant waxes, such as carnauba; mineral waxes, such as ozokerite; petroleum waxes, such as paraffin wax; synthetic waxes, such as polyethylene; and mixtures thereof. Suitable oil components may also be silicones including, but not limited to, volatile silicones such as cyclomethicone; polymeric silicones such as dimethicone; alkylated derivatives of polymeric silicones, such as cetyl dimethicone and lauryl trimethicone; hydroxylated derivatives of polymeric silicones, such as dimethiconol; and mixtures thereof. The aqueous component refers to any pharmaceutically or cosmetically acceptable material consisting essentially or predominantly of water.

For preparation of an oil-in water emulsion, the oil-in-water emulsifier will be an emulsifier having a hydrophilic-lipophilic balance (HLB) of at least 6, or a mixture of such emulsifiers with one or more water-in-oil emulsifiers (i.e., emulsifiers having an HLB of from about 2 to about 6), in which case the type and amount of each emulsifier present in the mixture is selected such that the effective HLB of the resultant oil-in-water emulsifier component is at least about 6. Techniques for combining and ascertaining the effective HLB of a mixture of emulsifiers are known; see L.M. Prince, in M.G. DeNavarre, "The Chemistry and Manufacture of Cosmetics", Volume III, Second Ed., (Continental Press, Orlando, 1975), pp. 25-37.

SUBSTITUTE SHEET (RULE 26)

Suitable oil-in-water emulsifiers include, but are not limited to, sorbitol derivatives, such as sorbitan monolaurate and polysorbate 20; ethoxylated alcohols such as laureth-23, ethoxylated fatty acids such as PEG-1000 stearate; amidoamine derivatives such as stearamidoethyl diethylamine; sulfate esters such as sodium lauryl sulfate; phosphate esters such as DEA cetyl phosphate; fatty acid amine salts such as TEA stearate; and mixtures thereof.

The emulsion may also be a water-in-oil emulsion. For this purpose, a water-in-oil emulsifier is employed. This refers to any cosmetically acceptable emulsifier having an HLB of no greater than 6, preferably from about 2 to about 4.

Suitable water-in-oil emulsifiers include, but are not limited to, sorbitan derivatives such as sorbitan laurate and sorbitan palmitate; alkoxylated alcohols such as laureth-4; hydroxylated derivatives of polymeric silicones, such as dimethicone copolyol; alkylated derivatives of hydroxylated polymeric silicones, such as cetyl dimethicone copolyol; glyceryl esters such as polyglyceryl-4 isostearate; beeswax derivatives such as sodium isostearoyl-2 lactylate; lecithin; and mixtures thereof.

The active component of the pharmaceutical or cosmetic compositions will depend on the intended purpose of the compositions. Examples of such active agents which may form part of the composition include, but are not limited to, those that improve or eradicate age spots, keratoses and wrinkles, analgesics, anesthetics, anti-acne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antipruritic agents, antiemetics, antmotion sickness agents, anti-inflammatory agents, antihyperkeratolytic agents, anti-dry skin agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging

SUBSTITUTE SHEET (RULE 26)

agents, antiwrinkle agents, antiasthmatic agents and bronchodilators, sunscreen agents, antihistamine agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, topical cardiovascular agents, clotrimazole, ketoconazole, miconazole, griseofulvin, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzene, erythromycin, tetracycline, clindamycin, meclocyline, hydroquinone, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol, propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, vitamin A palmitate, vitamin E acetate and mixtures thereof.

In one preferred embodiment, the composition is a sunscreen-containing composition. The term "sunscreen" as used herein refers to any material which is capable of protecting human skin from ultraviolet radiation having a wavelength of from about 280 to about 400nm, by effectively absorbing such radiation, and/or reflecting or scattering such radiation away from the surface of human skin. Suitable sunscreens for purposes of this invention include but not limited to, titanium derivatives such as titanium dioxide, especially titanium dioxide having an average particle size of from 10 to 100 nanometers, most especially titanium dioxide having an average particle size of from 10 to 100 nanometers and comprising a hydrophobic coating agent to minimize agglomeration; zinc derivatives such as zinc oxide, especially zinc oxide having an average particle size of from 10 to 100 nanometers; melanin and melanin derivatives; dioxybenzone; 2-ethylhexyl 2-cyano-3,3-diphenylacrylate; 2-ethylhexyl p-methoxycinnamate; 2-ethylhexyl

salicylate; homosalate; menthyl anthranilate; oxybenzone; octyl dimethyl PABA; red petrolatum; ferulic acid ester; and mixtures thereof.

In addition to those components specifically noted above, the compositions may also comprise additional preservatives, fragrances, emollients, antiseptics, antiinflammatories, antibacterials, stabilizers, antioxidants, vitamins, pigments, dyes, humectants, and propellants, as well as other classes of materials the presence of which in the compositions may be cosmetically, medicinally, or otherwise desired. Such components can be found in the CTFA International Cosmetics Ingredients Dictionary, *supra*.

The present invention is further illustrated by the following non-limiting examples.

15 EXAMPLE I

Thalaspheres® (30µm) containing hinokitiol are provided by Bioetica, Inc., Portland, Maine). The composition of the Thalaspheres®, in grams per 100g, is as follows:

20	Ingredient	Total	Support phase	Capsules composition
	Deionized water	81.494	77.86%	89.98%
	Butylene glycol	15.0	21.43%	
	Hinokitiol	2.4		8.0%
25	Xanthan gum	0.5	0.71%	
	atelocollagen	0.441		1.47%
	chondroitin	0.165		0.55%
<hr/>				
		100 g	100%	100%
30	equivalent (in g/100g of product)		70g	30g

EXAMPLE 2

The encapsulated hinokitiol, as described in Example 1, is incorporated by art-recognized procedures into a sunscreen-containing dispersion, a moisturizing cream emulsion, and a skin desensitizing lotion emulsion. The components are as follows:

SUNSCREEN FORMULATION

	<u>Component</u>	<u>Weight %</u>
10	cyclomethicone/dimethicone copolyol	16.0
	Titanium dioxide Dispersion	13.0
	cyclomethicone	15.5
	dimethicone	10.5
	phenyltrimethicone	6.0
15	hydrogenated lecithin	0.5
	deionized water	36.0
	magnesium sulfate	1.5
	encapsulated hinokitiol	1.0

MOISTURIZING FORMULATION

	<u>Component</u>	<u>Weight %</u>
20	Deionized water	62.0
25	oat stearate	0.9
	Disodium EDTA	0.1
	squalane	5.0
30	cetearyl alcohol/cetearyl glucoside	5.0
	shea butter	6.0
35	sucrose	2.0
	isostearyl neopentanoate	2.0
	cyclomethicone	7.5
40	carbomer	0.25

SUBSTITUTE SHEET (RULE 26)

	glycerine USP 95%	2.5
5	triethanolamine 99%	0.05
	sodium hyaluronate	2.5
	encapsulated hinokitiol	4.2

10

SKIN DESENSITIZING FORMULATION

	<u>Component</u>	<u>Weight %</u>
	Satin Finish*	50%
15	Disodium EDTA	0.1
	Shea butter	0.5
	rosemary extract	0.1
20	glycerine USP 95%	4.5
	gorgonian extract	0.1
25	aluminum starch octenyl succinate	1.2
	carbomer	0.2
	sucrose	1.8
30	caffeine powder	0.4
	triethanolamine 99%	0.05
35	magnesium aluminum sulfate	0.25
	deionized water	36.6
40	encapsulated hinokitiol	4.2

*a commercial (Collaborative Labs) emulsion comprising phenyl trimethicone, cyclomethicone, phosphoglycerides, dimethiconol, phenoxyethanol, carbomer, and triethanolamine

45

The formulations so prepared exhibit no deterioration, no discoloration and no unpleasant odor even after prolonged

SUBSTITUTE SHEET (RULE 26)

storage, showing the encapsulated hinokitiol retains its preservative effect while at the same time being stabilized by the encapsulation.

5 EXAMPLE 3

Hinokitiol alone is tested for its ability to prevent irritation. Hinokitiol (unencapsulated, 0.5% by weight) is applied to the ventral forearms of panelists. The material is allowed to absorb for twenty minutes and then Balsam of Peru, an irritant, is applied to the test sites. Skin irritation is measured in terms of increase in skin redness. Cola nitida (10% hydro-alcohol 1:1) is used as a positive control.

The degree of redness is measured with the Minolta chromameter and compared with the positive and negative controls. The positive control is the color of skin treated with Balsam of Peru alone and the negative control is the skin treated with cola material challenged as with the hinokitiol. Hinokitiol exhibits a 71% activity, as compared with an average of 67% for cola.

20 The encapsulated hinokitiol is then tested for its retained anti-irritant activity. Encapsulated hinokitiol, prepared as described above, is prepared in 4.2% and 2.8% aqueous solution. These solutions are tested against empty microcapsules, as well as against cola nitida (10% hydro-alcohol 1:1), using the same protocol as described in the previous example. Results show that the activity of the encapsulated hinokitiol at 4.2% is approximately equivalent to that of 10% cola (61% vs 64%, respectively) in reducing the onset of irritation due to Balsam of Peru. The lower concentration of hinokitiol capsules shows 53% activity, while empty microcapsules show 28% activity.

SUBSTITUTE SHEET (RULE 26)

What we claim is:

1. A cosmetic or pharmaceutical composition containing a preservative-effective amount of hinokitiol-containing
5 microcapsules, the microcapsules comprising a matrix containing collagen and a glycosaminoglycan.
2. The composition of claim 1, in which the matrix comprises
10 atelocollagen and chondroitin sulfate.
3. The composition of claim 1 in which the hinokitiol is present in the microcapsules in an amount of from 0.1-10% by weight.
- 15 4. The composition of claim 1 in which the microcapsules are present in an amount of from about 1-10%.
5. The composition of claim 1 which is in the form of a solution, colloidal dispersion, emulsion, suspension, cream,
20 lotion, gel, foam, or mousse.
6. The composition of claim 5 which is a dispersion.
7. The composition of claim 5 which is an emulsion.
25
8. The composition of claim 7 which is a water-in-oil emulsion.
9. The composition of claim 6 which also contains a sunscreen.
30
10. The composition of claim 9 in which the sunscreen is titanium dioxide.

SUBSTITUTE SHEET (RULE 26)

11. The composition of claim 10 in which the microcapsules are present in an amount of about 1-5%.

12. A food composition containing a preservative-effective amount of hinokitiol-containing microcapsules, the microcapsules comprising a matrix containing collagen and a glycosaminoglycan.

10 13. A method for preserving a pharmaceutical, food or cosmetic composition comprising adding to the composition a preservative effective amount of hinokitiol-containing microcapsules.

14. A method for reducing the irritating effects of a cosmetic or pharmaceutical composition on the skin comprising adding to the composition an anti-irritant effective amount of hinokitiol-containing microcapsules.

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09835**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 9/50

US CL :424/456

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/456

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,268,174 A (SAKUMA ET AL.) 07 December 1993, see entire document.	1-14
Y	US 5,395,620 A (HUC ET AL.) 07 March 1995, see entire document.	1-14

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 AUGUST 1997

Date of mailing of the international search report

29 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

Raj Bawa, Ph.D.

Facsimile No. (703) 305-3230

Telephone No. (703) 308-2351

Form PCT/ISA/210 (second sheet)(July 1992)*